• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Oric Pharmaceuticals, Inc. - Common Stock (NQ:ORIC)

7.500 -0.520 (-6.48%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Oric Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
June 05, 2026
From ORIC Pharmaceuticals
Via GlobeNewswire
News headline image
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
May 27, 2026
From ORIC Pharmaceuticals
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC
May 19, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC
May 12, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
ORIC® Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Updates
May 04, 2026
From ORIC Pharmaceuticals
Via GlobeNewswire
News headline image
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
May 01, 2026
From ORIC Pharmaceuticals
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC
April 28, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
ORIC Investors Have Opportunity to Join ORIC Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm
April 22, 2026
From Schall Law
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc. - ORIC
April 21, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
ORIC Investors Have Opportunity to Join ORIC Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm
April 15, 2026
From The Schall Law Firm
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC
April 14, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
April 03, 2026
From ORIC Pharmaceuticals
Via GlobeNewswire
News headline image
ORIC® Pharmaceuticals Reports Selection of Rinzimetostat RP3D in Combination with Darolutamide for Himalayas-1 Phase 3 Global Study with Dose Optimization Data Supporting Its Potential Best-in-Disease Profile
March 31, 2026
From ORIC Pharmaceuticals
Via GlobeNewswire
News headline image
ORIC® Pharmaceuticals to Report Combination Dose Optimization Data From Phase 1b Trial of Rinzimetostat in Patients with mCRPC
March 27, 2026
Company to host a conference call and webcast on Tuesday, March 31, 2026 at 4:30 pm ET 
From ORIC Pharmaceuticals
Via GlobeNewswire
News headline image
ORIC® Pharmaceuticals Announces Preclinical Rinzimetostat (ORIC-944) Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting
March 17, 2026
From ORIC Pharmaceuticals
Via GlobeNewswire
News headline image
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
March 06, 2026
From ORIC Pharmaceuticals
Via GlobeNewswire
News headline image
ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Updates
February 23, 2026
From ORIC Pharmaceuticals
Via GlobeNewswire
News headline image
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
February 06, 2026
From ORIC Pharmaceuticals
Via GlobeNewswire
News headline image
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
February 05, 2026
From ORIC Pharmaceuticals
Via GlobeNewswire
News headline image
ORIC® Pharmaceuticals Provides Operational Highlights for 2025 and Anticipated Upcoming Milestones
January 12, 2026
From ORIC Pharmaceuticals
Via GlobeNewswire
News headline image
ORIC® Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 06, 2026
From ORIC Pharmaceuticals
Via GlobeNewswire
News headline image
ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and 2L NSCLC Patients with EGFR Exon 20 Mutations at the ESMO Asia Congress 2025
December 05, 2025
From ORIC Pharmaceuticals
Via GlobeNewswire
News headline image
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
December 05, 2025
From ORIC Pharmaceuticals
Via GlobeNewswire
News headline image
ORIC® Pharmaceuticals Presents Enozertinib Data in NSCLC Patients with HER2 Exon 20 Mutations at the ESMO Asia Congress 2025
December 05, 2025
From ORIC Pharmaceuticals
Via GlobeNewswire
News headline image
ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and Previously Treated NSCLC Patients with EGFR Atypical Mutations at the ESMO Asia Congress 2025
December 04, 2025
From ORIC Pharmaceuticals
Via GlobeNewswire
News headline image
ORIC® Pharmaceuticals Announces Enozertinib (ORIC-114) Late-Breaking Oral Presentations in EGFR Atypical and EGFR exon 20 NSCLC at the ESMO Asia Congress 2025
December 03, 2025
Company to host a conference call and webcast on Saturday, December 6, 2025, at 8:00 pm ET 
From ORIC Pharmaceuticals
Via GlobeNewswire
News headline image
ORIC® Pharmaceuticals Announces Enozertinib (ORIC-114) Poster Presentation in HER2 exon 20 NSCLC at the ESMO Asia Congress 2025
December 01, 2025
Company to host a conference call and webcast on Saturday, December 6, 2025, at 8:00 pm ET 
From ORIC Pharmaceuticals
Via GlobeNewswire
News headline image
ORIC® Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare Conference
November 24, 2025
From ORIC Pharmaceuticals
Via GlobeNewswire
News headline image
ORIC® Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Clinical and Operational Updates
November 13, 2025
From ORIC Pharmaceuticals
Via GlobeNewswire
News headline image
ORIC® Pharmaceuticals Announces Completion of Dose Exploration Portion of ORIC-944 Phase 1b Clinical Trial and Continues to Demonstrate Potential Best-in-Class Efficacy and Safety
November 13, 2025
From ORIC Pharmaceuticals
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap